Open-label Extension for Phase 3 Clinical Trials of Simufilam
Status:
Enrolling by invitation
Trial end date:
2026-07-15
Target enrollment:
Participant gender:
Summary
The goal of this open-label extension study is to assess long-term safety and tolerability of
simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3
clinical trials.